A CRISPR Therapy Just Cured A Disease From Inside The Body For The First Time. The Gene-Editing Era Officially Started Monday ...

The gene editing treatment targets the relatively common 1717-1G>A splicing mutation, which does not respond to many current ...

As cell and gene therapy leaders gathered in Maryland to discuss accelerating clinical trials in children, one “cutting edge” ...

A phase 3 trial of Intellia Therapeutics’ in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...

You may have seen it in the news recently: a baby in Pennsylvania with a rare genetic disorder was healed with a personalized treatment that repaired his specific genetic mutation. The treatment was ...

Scientists at St. Jude Children’s Research Hospital report that they have developed an unbiased, sensitive, and resource-efficient method to identify small, off-target sites that pose a safety risk ...

Genetic editing holds promise to treat incurable diseases, but the most popular method — CRISPR — sometimes does more harm than good. A new study from University of California San Diego and Yale ...

In late April 2026, analysts highlighted expectations for higher year-over-year earnings and revenue at CRISPR Therapeutics ahead of its March-quarter report, alongside strong launch metrics for ...

A revolution is underway in gene editing—and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.

A looming $300 billion patent cliff by 2030 is spurring a surge in biotech M&A, with March 2026 alone seeing $31.5 billion in deals. Analysts highlight CRISPR Therapeutics, Intellia Therapeutics, and ...